The short version of bioavailability fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
=== Learning and memory === A study at the European Neuroscience Institute-Goettingen (Germany) found that fear extinction-induced IGF2/IGFBP7 signalling promotes the survival of 17- to 19-day-old newborn hippocampal neurons. This suggests that therapeutic strategies that enhance IGF2 signalling and adult neurogenesis might be suitable to treat diseases linked to excessive fear memory such as PTSD. The same group has found that IGFBP7 levels are increased in Alzheimer's disease and regulated via DNA methylation. Elevation of IGFBP7 in wild type mice causes memory impairment. Blocking IGFBP7 function in mice that develop Alzheimer's disease-like memory impairment restores memory function. These data suggest that IGFBP7 is a critical regulator of memory consolidation and might be used as biomarker for Alzheimer's disease. Targeting IGFBP7 could be a novel therapeutic avenue for the treatment of Alzheimer's disease patients.
The Cossack homelands were often very fertile, and during the collectivisation campaign many Cossacks shared the fate of the kulaks. According to historian Michael Kort, "During 1919 and 1920, out of a population of approximately 1.5 million Don Cossacks, the Bolshevik regime killed or deported an estimated 300,000 to 500,000". Others, such as Peter Holquist, estimate a figure of 10,000 deaths during this period, while a far greater number died during the engineered Soviet famines of 1932–33 and the Holodomor.
The Pidgeon process and the Bolzano process are similar. In both, magnesium oxide is the precursor to magnesium metal. The magnesium oxide is produced as a solid solution with calcium oxide by calcining the mineral dolomite, which is a solid solution of calcium and magnesium carbonates:
=== Dietary challenges === Adhering to the GFD can negatively impact those with coeliac disease, requiring major changes for an individual and their family. The restrictive nature of the GFD can lead to no longer enjoying food and pressure to be constantly vigilant about diet. The social life of those with coeliac disease is also negatively affected by the GFD. Cross-contamination—gluten-free food coming into contact with gluten—is a common worry for those eating away from home. Eating out may cause anxiety as it requires disclosing dietary restrictions and risking potential cross-contamination. Receiving a diagnosis of coeliac disease and the dietary changes required to manage the disorder can affect a person's relationship with food and lead to disordered eating as well as anxiety and depression. A diagnosis of coeliac disease can carry stigma, which may affect individuals' ability to seek help or disclose their condition when needed. Accessing gluten-free food can be a burden due to limited availability and variety, as well as higher costs compared to gluten-containing foods. Over the past ten years, the costs of gluten-free food have decreased; however, it remains significantly more expensive than gluten-containing food. There has been an increase in the popularity of the GFD among those without coeliac disease, which has improved the availability of gluten-free foods.
Prepare the recipient site of tissue exhibiting recession by incising the gingivae Obtain the SECT from the donor site Secure the SECT at the recipient site Suture the incised gingival tissue at both the donor and recipient sites The donor site might be sutured closed either before or after securing the donor tissue to the recipient site
Sources: en.wikipedia.org
In the July 2, 2026 issue of Federal Register (21 FR 1308), the federal government of the United States (through the Administrator of the Drug Enforcement Administration) issued a notice of intent to publish a temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16) under schedule I of the Controlled Substances Act. If issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
== Family and personal life == Kermani was born in Siegen as the fourth son of Iranian parents who immigrated to the Federal Republic of Germany in 1959. A medical doctor, his father worked at the Catholic St. Mary's Hospital in Siegen. Kermani's three older brothers are also practicing physicians. Navid Kermani has both German and Iranian citizenship. He grew up in the historically Protestant city of Siegen, where he attended the academic high schools Fürst-Johann-Moritz-Gymnasium and Gymnasium am Rosterberg (later renamed Peter-Paul-Rubens-Gymnasium). After graduating from high school, Kermani interned with Roberto Ciulli at the theater Theater an der Ruhr in the city of Mülheim before moving to Cologne in 1988 to pursue university studies. Until 2020, Kermani was married to Islamic studies scholar Katajun Amirpur; they are the parents of two daughters. Kermani has been a fan of the soccer club 1. FC Köln since 1971.
== History == The professional association began as the American Society for Medical Technology (ASMT) and is now known as the American Society for Clinical Laboratory Science (ASCLS). ASMT was organized in 1933 and incorporated in 1936. Early on, members were required to be certified by the Board of Registry (now the Board of Certification) of the American Society of Clinical Pathologists (ASCP) to ensure credibility of the society. During the 1930s, ASMT activities included the inception of a journal, the establishment of a Constitution and Bylaws, the emergence of state charters, and educating the public about the profession. In 1947, ASMT held its first independent convention, compared to earlier national meetings which were held in conjunction with physician groups. During the 1950s, the ASMT Research Fund was established to advance research efforts. In 1962, qualifications for the clinical laboratory scientist (medical technologist) changed to include a baccalaureate degree and a new category of laboratory technician emerged. Also in the 1960s, ASMT joined the International Association of Medical Laboratory Technologists. In the 1970s ASMT grew considerably in numbers (over 30,000 in 1976). The Professional Acknowledgment for Continuing Education (PACE) Program for validating and documenting continuing education was introduced, and the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) was formed as an independent accreditation agency.
=== Sexual deviance === CPA is used as an antiandrogen and form of chemical castration in the treatment of paraphilias and hypersexuality in men. It is used to treat sex offenders. The medication is approved in more than 20 countries for this indication and is predominantly employed in Canada, Europe, and the Middle East. CPA works by decreasing sex drive and sexual arousal and producing sexual dysfunction. CPA can also be used to reduce sex drive in individuals with inappropriate sexual behaviors, such as people with intellectual disability and dementia. The medication is also used to reduce sexual behavior diagnosed as self-harmful, such as masochism. CPA has comparable effectiveness to medroxyprogesterone acetate in suppressing sexual urges and function but appears to be less effective than GnRH modulators like leuprorelin and has more side effects. High-dose CPA significantly decreases sexual fantasies and sexual activity in 80 to 90% of men with paraphilias. In addition, it has been found to decrease the rate of reoffending in sex offenders from 85% to 6%, with most of the reoffenses being committed by individuals who did not follow their CPA treatment prescription. It has been reported that in 80% of cases, 100 mg/day CPA is adequate to achieve the desired reduction of sexuality, whereas in the remaining 20% of cases, 200 mg/day is sufficient. When only a partial reduction in sexuality is desired, 50 mg/day CPA can be useful.
=== SARS-CoV-2 === Rapamycin has been proposed as a treatment for severe acute respiratory syndrome coronavirus 2 insofar as its immunosuppressive effects could prevent or reduce the cytokine storm seen in very serious cases of COVID-19. Moreover, inhibition of cell proliferation by rapamycin could reduce viral replication.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.